CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
The release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".[1]Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.
$21B
1.00
